Autopsy report · NCT05755568

A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

“Company decision after projects re-evaluation, taken before the study initiation.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Takeda

Sponsor type

Industry

Conditions

Metachromatic Leukodystrophy (MLD)

Interventions

No Intervention

Participants

0

Sites

10

Countries

Spain

Trials that died the same way

• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
  “Company decision” (62% match in meaning)
• Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
  “Company decision not to start the study” (62% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (61% match in meaning)
• SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
  “The study was terminated early due to company decision” (61% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.